Precipio Announces Q2-2026 Financial Results
Rhea-AI Summary
Precipio (NASDAQ: PRPO) reported Q2-2026 revenue of $7.0M, up from $6.7M in Q1-2026 and 22% YoY versus $5.7M in Q2-2025. Revenue included $6.1M from pathology and $0.9M from product sales, both increasing sequentially.
According to the company, Adjusted EBITDA returned to positive at $0.4M, compared with $(0.2)M in Q1-2026 and $(0.1)M in Q2-2025, helped by higher revenue and lower stock-based compensation. Operating activities generated $0.7M in cash, contributing to a $0.5M total cash increase and quarter-end cash above $3M, versus $1.1M a year earlier. GAAP net loss for Q2-2026 was $(0.2)M compared with net income of $0.1M in Q2-2025.
Positive
- Revenue $7.0M in Q2-2026, up 22% YoY from $5.7M
- Product revenue $0.9M in Q2-2026, up from $0.66M in Q1-2026
- Adjusted EBITDA $0.4M in Q2-2026 vs. $(0.2)M in Q1-2026
- Operating cash flow $0.7M in Q2-2026, contributing to higher cash balance
- Quarter-end cash >$3M vs. $1.1M at end of Q2-2025
Negative
- GAAP net loss $(0.2)M in Q2-2026 vs. $0.1M net income in Q2-2025
- EBITDA $0.0M in Q2-2026 vs. $0.4M in Q2-2025
- Stock-based compensation $0.8M in Q2-2026 vs. $0.4M in Q2-2025
News Explained
The company has reported Q2 results for the quarter ended
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 14 | Q1 earnings report | Negative | -8.9% | Revenue growth accompanied by a larger net loss and negative adjusted EBITDA. |
| Nov 14 | Q3 earnings report | Positive | +8.8% | Revenue growth, positive adjusted EBITDA, and improved operating cash flow. |
| Aug 13 | Q2 earnings report | Positive | +2.9% | Revenue growth, improved margins, and reduced cash use supported the release. |
| May 14 | Q1 earnings report | Positive | +3.1% | Revenue growth and improved adjusted EBITDA and operating cash flow metrics. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings reactions varied, with positive responses in most comparable releases but a sharp negative response to the prior quarter's results.
Key Terms
adjusted ebitda financial
non-gaap financial
gaap financial
stock-based compensation expense financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Revenue reaches quarterly record as Precipio returns to positive Adjusted EBITDA and strengthens cash position
NEW HAVEN, Conn., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces financial results for the second quarter that ended June 30, 2026.
Below are some of the key financial performance metrics for the Company. For additional results please see the Company’s Form 10-Q which was filed today.
- Revenue –
$7.0M vs.$6.7M in Q1-2026, and up22% YoY from$5.7M in Q2-2025. This comprised of$6.1M in pathology revenue (up from$6.0M in Q1) and$0.9M in product revenue (up from$0.66M in Q1). - Adjusted EBITDA –
$0.4M vs.$(0.2)M in Q1-2026. The change was driven by increased revenues of$0.3 million and a decrease in stock based compensation expense of$0.2M . - Cash flow - Cash Flow generated from operations was
$0.7M in Q2-2026; total increase in cash was$0.5 million , resulting in an end of quarter cash balance exceeding$3M , vs$1.1M in Q2-2025.
“As anticipated, Q2 operating performance reflects a healthy recovery and continued momentum across the business, with customer growth generating quarterly revenue surpassing
Additional information and a more in-depth discussion on the Company’s Q2-2026 performance will be provided in the shareholder call on August 17th, 2026, at 5 PM ET. The call will include remarks by management on the Company’s core business, followed by a moderated Q&A session.
EBITDA and Adjusted EBITDA Reconciliation and Explanation
EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is a non-GAAP financial measure that is widely used to evaluate operational performance and pre-tax profitability of emerging growth companies like ours. Management believes Adjusted EBITDA provides investors with a useful perspective on the Company’s financial health, particularly where non-cash amortization has an important impact on profitability.
Adjusted EBITDA as we define it modifies EBITDA by excluding the non-cash costs of employee stock options and unusual non-operating income and expense. Below is a reconciliation of Net Income, EBITDA and Adjusted EBITDA for the second quarter of 2026 and 2025:
| ($ in millions, unaudited) | Q2-26 | Q2-25 | ||||
| Net income/(loss) (GAAP) | ) | |||||
| Adjustments to net income/(loss): | ||||||
| Interest expense, net | ||||||
| Income taxes | ||||||
| Depreciation | ||||||
| Amortization of intangibles | $0.2 | $0.2 | ||||
| EBITDA (non-GAAP) | ||||||
| Further Adjustments to EBITDA | ||||||
| Stock-based compensation expense | ||||||
| Other significant (income) expenses | $(0.4 | ) | ) | |||
| Adjusted EBITDA (non-GAAP) | ) | |||||
About Precipio
Precipio is a healthcare biotechnology company focused on cancer diagnostics. Our mission is to address the pervasive problem of cancer misdiagnoses by developing solutions in the form of diagnostic products and services. Our products and services deliver higher accuracy, improved laboratory workflow, and ultimately better patient outcomes, which reduce healthcare expenses. Precipio develops innovative technologies in our laboratory where we design, test, validate, and use these products clinically, improving diagnostic outcomes. Precipio then commercializes these technologies as proprietary products that serve the global laboratory community and further scales Precipio’s reach to eradicate misdiagnosis.
Availability of Other Information About Precipio
For more information, please visit the Precipio website at https://www.precipiodx.com/ or follow Precipio on X (formerly Twitter) (@PrecipioDx) and LinkedIn (Precipio) and on Facebook. Investors and others should note that we communicate with our investors and the public using our company website (https://www.precipiodx.com), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the targets set herein and related timing. Except for historical information, statements about future volumes, sales, growth, costs, cost savings, margins, earnings, earnings per share, diluted earnings per share, cash flows, adjusted EBITDA, plans, objectives, expectations, growth or profitability and our potential to reach financial independence are forward-looking statements based on management’s estimates, beliefs, assumptions and projections. Words such as “could,” “may,” “expects,” “anticipates,” “will,” “targets,” “goals,” “projects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “predicts,” and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance, are intended to identify such forward-looking statements. These forward-looking statements are only predictions based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and our other reports filed with the U.S. Securities and Exchange Commission. Any such forward-looking statements represent management’s estimates as of the date of this press release only. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Inquiries: investors@precipiodx.com +1-203-787-7888 Ext. 523